Orders in 2016 rose by 70% as more life science company customers started to evaluate the technology
Showing 25 of 5301
The board members will advise Collagen on opportunities in regenerative medicine
The company, which has developed short course inoculations against hay fever, said turnover was £40.4mln in the six months ended December 31.
Prior to joining Motif Bio, Dickey was CFO at Tyme Technologies Inc., a NASDAQ-listed clinical stage oncology company
Christina Wood will join the board in due course subject to the necessary due diligence
“Summit has two strong scientific programmes with the potential to significantly advance the current standard of care in their respective disease areas," said new COO Dr David Roblin.
Clinigen’s Idis Managed Access division is helping Tesaro to run an early access programme for its niraparib drug
Horizon has strengthened its gene-editing capabilities by extending its key CRISPR licence
Officials will assess the technology's potential to check for hazards such as biological warfare agents.
The two abstracts to be presented relate to OptiBiotix’s work on its cholesterol lowering probiotic
The data appeared in Science Translational Medicine and resulted from a collaboration with the National Institute of Allergy and Infectious Diseases in the US.
US officials said Shire Pharmaceuticals will pay $350m to settle allegations that it used “kickbacks and other unlawful methods” to induce doctors to use a product aimed at treating foot ulcers
China was a trail-blazer as its turnover grew just short of 30%.
The cash from the offering will be used to accelerate growth in the US and international markets
Clinigen and Cumberland formed their alliance last year and have already launched one drug, Ethyol
Biovault is now a member of CellPlan's Excel Membership Programme, which is focused on maintaining operating excellence within the stem cell industry
Dr Raymond Barlow brings with him a “broad experience of drug discovery, development and commercialisation, acquired through regional and global roles in the biotech and pharmaceutical sector”, ETX said.
Paul Devlin brings a wealth of experience that will be invaluable to the company as it ups its commercial activity
From its initial float in 2014, the firm has grown three drug programmes to now eight programmes
Per Rehné has worked for some of the world's leading food companies, including Danisco, Frutarom Nordic and Innotaste Nordic
EuroTec manufactures and distributes one- and two-piece ostomy systems and accessories
The group said he subscribed for 36,917 new shares at 7.45p each worth around £2,750.
The support from Silicon Valley Bank is a further demonstration of the continuing commercialisation of the company
OptiBiotix Health has kicked off the New Year by increasing its investment in subsidiary The Health Weight Loss Company Limited (THWLC)
The notes were converted at 5.625p a share, versus a current share price of 5.15p..